Companies ›Healthcare ›GOSS.TA

GOSS.TA — TASE (Tel Aviv) Biotechnology & Life-Science Tools

Goss.Ta

$1 127,00

Open in Charts → Attach watcher ⌖

— —

ILA

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

92,0B ILA

P/E

—

EV / Rev

—

Div yield

2,24 %

Op margin

5,7 %

ROE

22,8 %

Net margin

3,8 %

Debt / equity

0,61

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

GOSS.TA provides industrial services within the business support services industry, generating revenue primarily through its operations in the industrial and commercial services sector.

Business. Gossamer Bio Inc (GOSS.O) is a biotechnology company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not provided, the company is described at the industry level as an entity engaged in healthcare diagnostics and biotechnology activities.

Classification99 %

SectorHealth Care

Industry groupBiotechnology & Life-Science Tools

Generated · model-assisted

Sell-side consensus

HOLD10 analysts

4 buy5 hold1 sell

Avg 12m price target4,35

Analyst recommendations

10 analysts · consensus Hold

Buy4

Hold5

Sell1

12-month price target

4,35

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Hold

10 analysts · indicative

Ownership→

JPMorgan Private Bank (United States)

largest disclosed fund holder

Profitability→

22,8 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning GOSS.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to GOSS.TA. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Gossamer Bio Inc (GOSS.O) is a biotechnology company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not provided, the company is described at the industry level as an entity engaged in healthcare diagnostics and biotechnology activities.

Classification99 %

SectorHealth Care

Industry groupBiotechnology & Life-Science Tools

AI synthesis

GENERATED

GOSS.TA maintains a capital structure with a debt-to-equity ratio of 0.61, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.07, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's cash and equivalents amount to only 3.8 million, which is significantly lower than its long-term debt of 102.8 million, resulting in a net cash position that is negative after subtracting total debt.

In terms of profitability, GOSS.TA reports a return on equity (ROE) of 22.81% and a return on assets (ROA) of 6.94%. These figures are relatively strong, but the company's price-to-earnings (P/E) ratio of 2357.71 and price-to-book (P/B) ratio of 537.83 suggest that the market is valuing the company at a premium compared to its earnings and book value. This valuation is further supported by an enterprise value to EBITDA (EV/EBITDA) ratio of 1590.69, which is significantly higher than typical industry benchmarks.

The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the primary segment or region experiences a downturn. The lack of detailed segment and geographic breakdown in the provided data limits the ability to assess the full extent of revenue concentration.

GOSS.TA's growth trajectory is not clearly defined in the provided data, as there are no specific revenue growth projections or historical growth rates available. The company's capital expenditure of -5.7 million indicates a reduction in investment in physical assets, which could signal a focus on cost optimization or a strategic shift in capital allocation. The absence of detailed outlook data for the current and next fiscal years makes it challenging to assess the company's future growth potential.

The risk assessment for GOSS.TA highlights a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative net cash position after accounting for total debt. The dilution risk is considered low, as there is no indication of significant share issuance or dilution potential in the near term. The company's financial structure and the absence of dilutive events in the provided data support this assessment.

Recent events and filings for GOSS.TA do not provide specific details on new product launches, strategic partnerships, or significant operational changes. The company's financial statements and risk assessment do not mention any recent regulatory issues or major legal proceedings that could impact its operations or financial performance. The lack of detailed recent events data limits the ability to assess the company's current strategic direction and operational health.

Key takeaways

GOSS.TA has a strong return on equity (22.81%) but is valued at a very high P/E ratio (2357.71), indicating a premium valuation.
The company's liquidity position is moderate, with a current ratio of 1.07 and a negative net cash position after subtracting total debt.
Revenue concentration in a single segment and lack of geographic diversification may increase operational risk.
The company's capital expenditure is negative, suggesting a focus on cost optimization or a strategic shift in capital allocation.
Dilution risk is low, with no significant share issuance or dilution potential in the near term.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$1 127,00

Market cap

$91.14B

Enterprise valueⓘ

$91.24B

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

1573.6x

P / Bⓘ

537.8x

P / Tangible bookⓘ

537.8x

Tangible book

$169.5M

Net cashⓘ

-$99.0M

Current ratioⓘ

1.1

Debt / equityⓘ

0.6

ROAⓘ

6.9%

ROEⓘ

22.8%

Cash conversionⓘ

150.0%

CapEx / revenueⓘ

-0.6%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships3 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries3

EX21:501c32866187EX21:501c32866187Subsidiarie97%

EX21:d0f01c789a4cEX21:d0f01c789a4cSubsidiarie97%

EX21:f6b01628a497EX21:f6b01628a497Subsidiarie97%

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs GOSS · multiples and returns

IQV—

Iqvia Holdings Inc

$181,94

30,9B USD

P/E

22,7x

— vs self

Div yield

—

— vs self

ROE

21,9 %

+178,8 vs self

CRL—

Charles River Laboratories

$230,87

11,4B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-4,6 %

+152,3 vs self

MEDP—

Medpace Holdings Inc

$576,00

16,7B USD

P/E

34,4x

— vs self

Div yield

—

— vs self

ROE

75,4 %

+232,3 vs self

ALKS—

Alkermes PLC

$49,53

8,2B USD

P/E

39,8x

— vs self

Div yield

—

— vs self

ROE

8,4 %

+165,3 vs self

PIII—

P3 Health Partners Inc

$10,20

73,8M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

95,3 %

+252,2 vs self

ORGO—

Organogenesis Holdings Inc

$2,38

306,2M USD

P/E

9,0x

— vs self

Div yield

—

— vs self

ROE

8,5 %

+165,4 vs self

NAGE—

Niagen Bioscience Inc

$3,53

281,1M USD

P/E

17,4x

— vs self

Div yield

—

— vs self

ROE

22,7 %

+179,6 vs self

SPRY—

Ars Pharmaceuticals Inc

$5,51

547,1M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-149,9 %

+7,0 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,46

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-16 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$0,30

Mean$4,35

Median$2,00

High$15,00

Spot$1 127,00

−99.6 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin5,7 %Above P75

Net Margin3,8 %Above P75

ROE22,8 %Above P75

Capex / Rev-0,6 %Above median

D/E0,61Bottom quartile

Cash Conv1,50Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 5 201 250 sh64 grants12 insiders

Daniel Thomas ODirector · Stock Option (Right to Buy) → Common StockAcquired 115 000 @ $0,18grant · 2026-06-04
Cox Russell J.Director · Stock Option (Right to Buy) → Common StockAcquired 115 000 @ $0,18grant · 2026-06-04
Milligan SandraDirector · Stock Option (Right to Buy) → Common StockAcquired 115 000 @ $0,18grant · 2026-06-04
Nathan Steven DDirector · Stock Option (Right to Buy) → Common StockAcquired 115 000 @ $0,18grant · 2026-06-04
Quisel John DDirector · Stock Option (Right to Buy) → Common StockAcquired 115 000 @ $0,18grant · 2026-06-04
Drynan SkyeDirector · Stock Option (Right to Buy) → Common StockAcquired 115 000 @ $0,18grant · 2026-06-04
Aranda RichardChief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 40 000 @ $1,36disposition · 2026-03-19
Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 47 667 @ $1,36disposition · 2026-03-19
Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 60 000 @ $1,36disposition · 2026-03-19
Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 126 667 @ $1,36disposition · 2026-03-19
Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 157 500 @ $1,21disposition · 2026-03-19
Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 125 000 @ $0,84disposition · 2026-03-19
Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 375 000 @ $0,97disposition · 2026-03-19
Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 440 000 @ $1,13disposition · 2026-03-19
Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 506 250 @ $2,88disposition · 2026-03-19
Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 96 667 @ $0,45grant · 2026-03-19
Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 47 667 @ $0,45grant · 2026-03-19
Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 60 000 @ $0,45grant · 2026-03-19
Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 100 000 @ $0,45grant · 2026-03-19
Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 176 667 @ $0,45grant · 2026-03-19
Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 211 500 @ $0,45grant · 2026-03-19
Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 181 250 @ $0,45grant · 2026-03-19
Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 543 750 @ $0,45grant · 2026-03-19
Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 638 000 @ $0,45grant · 2026-03-19
Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 693 750 @ $0,45grant · 2026-03-19

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Ev To Operating Cash Flow
enterprise_value / operating_cash_flow
Return On Equity
net_income / total_equity
Price To Earnings
market_price / (net_income / shares_outstanding_diluted)
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)

Source documents

GOSS.TA Market data — financials · 2026-05-28

Ownership & reference

Top holders

JPMorgan Private Bank (United States)Investment Managers · as of 2026-03-310,15 %$2M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$3M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$6M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$40M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$2M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$3M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$1M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Insider activity

Net buying1 buys · 0 sellsnet $50K7 insiders · last 365d

Hasnain FaheemDirector, President & CEO · Common StockOther 280 000 · 2026-01-02
Giraudo BryanCOO/CFO · Common StockOther 115 750 · 2026-01-02
Smith Robert Paul JRChief Commercial Officer · Common StockOther 93 750 · 2026-01-02
Aranda RichardChief Medical Officer · Common StockOther 93 750 · 2026-01-02
Peterson CarynEVP, Regulatory Affairs · Common StockOther 84 500 · 2026-01-02
Christian WaageEVP, Tech Ops and Admin · Common StockOther 84 500 · 2026-01-02
Smith Robert Paul JRChief Commercial Officer · Common StockOther 162 500 · 2025-10-01
Christian WaageEVP, Tech Ops and Admin · Common StockOther 125 000 · 2025-10-01
Giraudo BryanCOO/CFO · Common StockOther 181 250 · 2025-10-01
Aranda RichardChief Medical Officer · Common StockOther 162 500 · 2025-10-01
Hasnain FaheemDirector, President & CEO · Common StockOther 437 500 · 2025-10-01
Peterson CarynEVP, Regulatory Affairs · Common StockOther 125 000 · 2025-10-01
Milligan SandraDirector · Common StockBought 26 050 @ $1,92$50K · 2025-08-19

Short positioning

73.2Mshares short+36.3% vs prior

3.79days to cover

69.2%short of daily vol

274.1Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

GOSS.TACanonical

TASE (Tel Aviv) · ILA

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -200.0%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -4,838.5%Derived (calculated)
Debt-to-equity (FY 2025-12-31): -2.40xDerived (calculated)
Current ratio (FY 2025-12-31): 2.64xDerived (calculated)
Return on assets (FY 2025-12-31): -98.9%Derived (calculated)
Return on equity (FY 2025-12-31): 138.8%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -200.0%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -18.1%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -201.4%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -45.4%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -184.9%Derived (calculated)
Net margin (FY 2025-12-31): -351.5%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -516.2%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): -57.7%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 3.2%Derived (calculated)
Current liabilities (annual): USD 63.44MSEC XBRL filing
Current assets (annual): USD 167.64MSEC XBRL filing
Operating cash flow (annual): USD -171.27MSEC XBRL filing
Total liabilities (annual): USD 295.01MSEC XBRL filing
Shares outstanding (annual): 233.68MSEC XBRL filing
Total operating expenses (annual): USD 219.2MSEC XBRL filing
Revenue (annual): USD 48.47MSEC XBRL filing
Net income (annual): USD -170.37MSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-08-04 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-07-29 22:34 UTCEVENTHa Price Listing GOSS remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 105 consecutive trading days (last close $0.14). cure deadline 2027-01-17 (172 days remaining).

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-17FILING8-K filing →

2026-06-09FILINGDEF 14A filing →

2026-06-05FILING8-K filing →

2026-06-04 00:00 UTCINSIDER6 insider transactions — 2026-06 6 derivative

2026-06-04INSIDERMilligan Sandra acquired 115.0k sh Stock Option (Right to Buy) — Director

2026-06-04INSIDERDaniel Thomas O acquired 115.0k sh Stock Option (Right to Buy) — Director

2026-06-04INSIDERDrynan Skye acquired 115.0k sh Stock Option (Right to Buy) — Director

2026-06-04INSIDERQuisel John D acquired 115.0k sh Stock Option (Right to Buy) — Director

2026-06-04INSIDERNathan Steven D acquired 115.0k sh Stock Option (Right to Buy) — Director

2026-06-04INSIDERCox Russell J. acquired 115.0k sh Stock Option (Right to Buy) — Director

2026-06-02FILING8-K filing →

2026-05-18FILING8-K filing →

2026-05-15FILING10-Q filing →

2026-04-24FILINGDEF 14A filing →

2026-04-09FILING8-K filing →

2026-03-19 00:00 UTCINSIDER104 insider transactions — 2026-03 104 derivative

2026-03-19INSIDERAranda Richard disposed of 157.5k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard disposed of 562.5k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard disposed of 572.0k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard disposed of 487.5k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard disposed of 162.5k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard disposed of 126.7k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard disposed of 20.0k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard disposed of 40.0k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard disposed of 22.8k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard disposed of 9.2k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard disposed of 30.0k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard acquired 562.5k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard acquired 572.0k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERAranda Richard acquired 487.5k sh Stock Option (Right to Buy) — Chief Medical Officer

2026-03-19INSIDERHasnain Faheem disposed of 325.0k sh Stock Option (Right to Buy) — Director, President & CEO

2026-03-19INSIDERHasnain Faheem disposed of 47.0k sh Stock Option (Right to Buy) — Director, President & CEO

2026-03-19INSIDERHasnain Faheem disposed of 43.5k sh Stock Option (Right to Buy) — Director, President & CEO

2026-03-19INSIDERHasnain Faheem acquired 1.68M sh Stock Option (Right to Buy) — Director, President & CEO

2026-03-19INSIDERHasnain Faheem acquired 1.54M sh Stock Option (Right to Buy) — Director, President & CEO

Showing the 40 most recent of 59 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread